An £8.7 million, five-year research collaboration led by The University of Edinburgh and FUJIFILM Diosynth Biotechnologies UK (FDB) will develop more cost-effective ways to make modern antibody-based medicines. Image Robots at the Edinburgh Genome Foundry With the support of Edinburgh Innovations, the collaboration has won Prosperity Partnership funding from the Engineering and Physical Sciences Research Council (EPSRC) and the Biotechnology and Biological Sciences Research Council (BBSRC), both of which are part of UK Research and Innovation. The partnership will use state-of-the-art analytical tools and engineering biology approaches to enable costeffective manufacturing of biological drugs. Biological drugs based on recombinant DNA technology, which brings together genetic material from different sources, have transformed the treatment of life-limiting diseases including cancer, haemophilia and rheumatoid arthritis. "Only by working together can academic researchers and commercial businesses both maximise the impact of their work, for mutual benefit and common goals." Dr George Baxter, CEO, Edinburgh Innovations Find out more To read the full story visit: https://edin.ac/3jYBUpm This article was published on 2024-07-01
